Interstitial lung abnormalities (ILAs) are parenchymal lung changes found on high-resolution CT. In routine use of high-resolution CT, non-specific findings are frequently reported, which has prompted ...

The global progressive pulmonary fibrosis (PPF) treatment market is projected to be valued at USD 4,044.6 Million in 2025 and is expected to reach USD 8,182.4 Million by 2035, registering a CAGR of 7.

A 79-year-old man with recurrent oropharyngeal cancer has developed the first documented case of severe drug-induced interstitial lung disease following photoimmunotherapy with cetuximab-sarotalocan ...

According to data from the Health Insurance Review and Assessment Service in 2023, there are an estimated 15,000 patients ...

The FDA granted accelerated approval to the tyrosine kinase inhibitor sunvozertinib (Zegfrovy) for advanced non-small cell ...

Fibroblasts reprogrammed into AT2-like lung cells in just 7–10 days, offering a faster, safer alternative to stem cell ...

Arturo Loaiza-Bonilla, MD, MSEd, systemwide chief of hematology and oncology at St. Lukes University Health Network and ...

The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of Ofev (nintedanib) for the treatment of adults with interstitial lung disease caused by systemic sclerosis ...

The FDA has approved Zegfrovy (sunvozertinib) for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.

HER3-DXd demonstrated activity in a phase 3 trial of patients with previously treated, EGFR-mutant NSCLC, but the BLA for HER3-DXd has been withdrawn.

The US Food and Drug Administration (FDA) has granted accelerated approval to Zegfrovy (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC ...

Cleveland Clinic Abu Dhabi is one of the few hospitals around the world to have performed Robotic lung transplant surgery ...